GlassScriptPhysician profile
Joshua Daniel Cohen
NPI 1124462072
$11,944.71
in general payments reported to CMS, 2019-2025
31 companies · $2,641 in 2025
The $2,641 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $652 · 2021: $1,496 · 2022: $3,312 · 2023: $1,450 · 2024: $1,529 · 2025: $2,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,522 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,522.11 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,884.91 | 2019-2025 | |
| Abbvie INC. | $1,213.13 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Alcon Vision LLC | $876.07 | 2019-2025 | Wavelight Refractive Suite, Clareon, Unity |
| Bausch & Lomb Americas INC. | $655.86 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $598.04 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $528.03 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $519.32 | 2020-2025 | Veritas Vision System, Tecnis Iol, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $510.65 | 2019-2021 | |
| Rxsight INC | $485.10 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Mallinckrodt Hospital Products INC. | $471.75 | 2024-2025 | Acthar |
| Horizon Therapeutics Plc | $456.72 | 2021-2023 | Tepezza |
| Dompe US, INC. | $453.93 | 2019-2025 | Oxervate |
| New World Medical,INC. | $380.40 | 2022-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Rayner Intraocular Lenses Limited | $322.01 | 2022-2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Glaukos Corporation | $313.73 | 2025 | Photrexa Viscous and Photrexa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $276.32 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $272.14 | 2020-2022 | |
| Harrow Eye, LLC | $271.86 | 2024-2025 | Vevye |
| Galderma Laboratories, L.P. | $256.65 | 2019-2022 | |
| Amgen INC. | $234.27 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $211.38 | 2020-2023 | |
| Sight Sciences, INC. | $154.91 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $124.99 | 2022 | |
| Aerie Pharmaceuticals, INC. | $124.99 | 2019 | |
| Abbott Laboratories | $98.65 | 2024 | |
| Oyster Point Pharma, INC. | $78.77 | 2022-2025 | Tyrvaya, Ryzumvi |
| Lensar, INC. | $76.16 | 2022 | |
| Shire North American Group INC | $38.96 | 2019 | |
| Kala Pharmaceuticals, INC. | $19.62 | 2021 | |
| Akorn, INC. | $19.26 | 2019 | |
| Astellas Pharma US INC | $16.13 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.